A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer

• Published in: Breast cancer research and treatment Vol. 133; no. 3; pp. 1049 - 1056
• Main Authors: Carlson, Robert W., O’Neill, Anne, Vidaurre, Tatiana, Gomez, Henry L., Badve, Sunil S., Sledge, George W.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.06.2012; Springer; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Cancer; Cancer research; Cancer therapies; Care and treatment; Clinical Trial; Clinical trials; Diarrhea; Drug therapy; Estradiol - administration & dosage; Estradiol - analogs & derivatives; Estrogen; Female; Gefitinib; Gynecology. Andrology. Obstetrics; Hormones; Humans; Mammary gland diseases; Medical sciences; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Neoplasm Metastasis; Nitriles - administration & dosage; Oncology; Pharmacology. Drug treatments; Postmenopausal women; Quinazolines - administration & dosage; Receptors, Estrogen - metabolism; Receptors, Progesterone - metabolism; Survival Analysis; Treatment Outcome; Triazoles - administration & dosage; Tumors; Metastatic breast cancer; Gefitinib; Anastrozole; Randomized phase II; Fulvestrant; Antineoplastic agent; Estrogen receptor; Breast disease; Azole derivatives; Quinazoline derivatives; Menopause; Antiestrogen; Antihormone; Estrogen synthase; Metastasis; EGFR tyrosine kinase inhibitor; Randomization; Phase II trial; Postmenopause; Adult; Clinical trial; Female; Advanced stage; Antagonist; Woman; Non steroid compound; Protein-tyrosine kinase; Human; Drug; Drug combination; Aromatase inhibitor; Enzyme; Tyrosine kinase inhibitor; Transferases; Enzyme inhibitor; Breast cancer; Malignant tumor; Mammary gland diseases; Chemotherapy; Treatment; Triazole derivatives; Cancer; Hormonal receptor

EGFR signalling pathways appear involved in endocrine therapy resistance in breast cancer. This trial estimates the antitumor efficacy and toxicity of the EGFR tyrosine kinase inhibitor gefitinib in combination with anastrozole or fulvestrant in postmenopausal hormone receptor positive breast cancer...